

CITATION REPORT

List of articles citing

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer

DOI: 10.1016/j.eururo.2011.11.009
European Urology, 2012, 61, 549-59.

Source: <https://exaly.com/paper-pdf/54529361/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
151	From bench to bedside: the realities of reducing global prostate cancer disparity in black men. 2014 , 8, 458		6
150	Prostate cancer - a biomarker perspective. 2012 , 3, 72		21
149	Current world literature. 2012 , 24, 454-60		
148	The role of genetic markers in the management of prostate cancer. <i>European Urology</i> , 2012 , 62, 577-87	10.2	86
147	Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). 2012 , 61, 2283-94		22
146	[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]. 2012 , 99, 875-80		4
145	A case of abiraterone acetate withdrawal. <i>European Urology</i> , 2013 , 64, 517-8	10.2	12
144	Optimal therapy sequencing in metastatic castration-resistant prostate cancer. 2013 , 15, 217-23		1
143	Current, new and novel therapy for castration-resistant prostate cancer. 2013 , 13, 819-27		7
142	[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment]. 2013 , 23 Suppl 1, S44-8		0
141	Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition. 2013 , 8, 403-416		
140	Novel therapies for the treatment of advanced prostate cancer. 2013 , 14, 109-26		15
139	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013 , 15, 342-9	2.8	23
138	Blood-based biomarkers for malignant gliomas. 2013 , 113, 345-352		28
137	Chip-based nanostructured sensors enable accurate identification and classification of circulating tumor cells in prostate cancer patient blood samples. 2013 , 85, 398-403		45
136	Emerging methods for disease monitoring in malignant gliomas. 2013 , 2, 511-22		10
135	Controversies in circulating tumor cell count during therapy. 2013 , 13, 499-507		4

134	Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. 2013 , 88, 357-67		4
133	Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. 2013 , 19, 25-33		10
132	Perspectives on treatment of metastatic castration-resistant prostate cancer. 2013 , 18, 558-67		24
131	Targeted α -particle therapy of bone metastases in prostate cancer. 2013 , 38, 966-71		38
130	Circulating tumour cells: insights into tumour heterogeneity. 2013 , 274, 137-43		37
129	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. 2013 , 9, 889-97		27
128	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. 2013 , 109, 121-30		15
127	Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. 2013 , 9, 899-907		30
126	Microfluidic chip coupled with modified paramagnetic particles for sarcosine isolation in urine. 2013 , 34, 2639-47		22
125	Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. 2013 , 2013, 1-14		4
124	Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line. 2013 , 29, 2459-66		5
123	Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. <i>Asian Journal of Andrology</i> , 2013 , 15, 110-5	2.8	25
122	BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. <i>PLoS ONE</i> , 2013 , 8, e52993	3.7	21
121	Building on Prostate Cancer Working Group 2 to change the paradigm from palliation to cure. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e204-12	7.1	1
120	Prostate cancer: incorporating genomic biomarkers in prostate cancer decisions. 2014 , 11, 605-612		2
119	Cancer-related inflammation: an emerging prognostic domain in metastatic castration-resistant prostate carcinoma. 2014 , 120, 3272-4		6
118	Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?. 2014 , 14, 1257-60		3
117	Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos. <i>Prostate</i> , 2014 , 74, 1079-85	4.2	6

116	Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. 2014 , 10, 205-15		5
115	Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. 2014 , 7, 137-46		13
114	Prostate cancer: measuring PSA. 2014 , 44, 433-40		60
113	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014 , 74, 1222-30	4.2	25
112	Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. 2014 , 6, 245-52		11
111	Personalizing prostate cancer therapy: the way forward. 2014 , 19, 1483-7		7
110	Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. 2014 , 32, 1136-42		229
109	Epithelial plasticity in prostate cancer: principles and clinical perspectives. 2014 , 20, 643-51		18
108	Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. <i>European Urology</i> , 2014 , 65, 875-83	10.2	62
107	New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?. <i>European Urology</i> , 2014 , 65, 300-2	10.2	2
106	Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014 , 50, 1617-27	7.5	120
105	Determination of common urine substances as an assay for improving prostate carcinoma diagnostics. 2014 , 31, 1846-54		26
104	Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism. 2015 , 16, 28943-78		24
103	The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study. 2015 , 2015, 812815		5
102	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. 2015 , 1, 582-91		44 ¹
101	Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. 2015 , 9, 122-7		20
100	Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. 2015 , 15, 649-66		5
99	Making progress on progression in metastatic prostate cancer. 2015 , 33, 1322-4		3

98	Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. 2015 , 16, 473-85		18
97	Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. 2015 , 15, 339-48		7
96	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 2015 , 26, 1589-604		220
95	Using circulating tumor cells to inform on prostate cancer biology and clinical utility. 2015 , 52, 191-210		15
94	cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer. 2015 , 194, 966-71		32
93	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. 2015 , 21, 3170-7		42
92	Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients. <i>BMC Cancer</i> , 2015 , 15, 458	4.8	19
91	Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review. 2015 , 26, 2221-47		7
90	Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. 2015 , 121, 361-71		8
89	Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. 2016 , 17,		6
88	New Markers for Prostate Cancer Detection and Prognosis. 2016 , 623-632		2
87	The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. <i>Diagnostics</i> , 2016 , 6,	3.8	15
86	Influence of Long-Distance Bicycle Riding on Serum/Urinary Biomarkers of Prostate Cancer. 2016 , 17, 377		3
85	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. 2016 , 7, 123		26
84	Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines. <i>Prostate</i> , 2016 , 76, 679-90	4.2	11
83	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. 2016 , 22, 5713-5721		26
82	Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. <i>Prostate</i> , 2016 , 76, 1257-70 ²		147
81	Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. 2016 , 16, 27		10

80	Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial. <i>BMC Cancer</i> , 2016 , 16, 231	4.8	5
79	Progress in the mechanism and drug development of castration-resistant prostate cancer. 2016 , 8, 765-88		6
78	Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. 2016 , 21, 1155-1161		16
77	Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. <i>Prostate</i> , 2016 , 76, 48-57	4.2	18
76	Employing dynamical computational models for personalizing cancer immunotherapy. 2016 , 16, 1373-1385		19
75	The oncologists' clinical needs for imaging in advanced prostate cancer. 2016 , 4, 423-431		2
74	Sequencing Treatment for Castration-Resistant Prostate Cancer. 2016 , 17, 64		26
73	Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. 2016 , 34, 490-501		7
72	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. 2016 , 48, 25-33		18
71	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 2016 , 34, 1402-18		666
70	Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT. 2016 , 57, 1058-64		13
69	Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. <i>BMC Cancer</i> , 2016 , 16, 168	4.8	54
68	The prognostic significance of OCT4 expression in patients with prostate cancer. 2016 , 51, 1-8		18
67	Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker. 2017 , 16, 998-1008		42
66	A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy. 2017 , 49, 61-67		9
65	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017 , 71, 168-171	10.2	38
64	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. 2017 , 120, E30-E44		47
63	Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy. <i>BMC Cancer</i> , 2017 , 17, 789	4.8	0

62	Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review. <i>Asian Journal of Andrology</i> , 2017 , 19, 196-202	2.8	26
61	Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancer. 2017 , 17, 40		4
60	The EEF1A2 gene expression as risk predictor in localized prostate cancer. 2017 , 17, 86		11
59	Castration-Resistant Prostate Cancer. 2018 , 297-322		
58	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. 2018 , 18, 155-163		33
57	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. 2018 , 8, 288-303		76
56	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. 2018 , 4, 529-539		24
55	Medical Prevention and Treatment of Bone Metastases. 2018 , 799-808		
54	Current therapeutic options in metastatic castration-resistant prostate cancer. 2018 , 45, 303-315		40
53	Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. 2018 , 22, 381-390		3
52	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. 2018 , 24, 5635-5644		59
51	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018 , 1, 151-159	6.7	23
50	Clinical utility of bone markers in various diseases. <i>Bone</i> , 2018 , 114, 215-225	4.7	31
49	Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. <i>Prostate</i> , 2019 , 79, 604-613	4.2	27
48	NMR-Based Metabolomic Profiling of Urine: Evaluation for Application in Prostate Cancer Detection. <i>Natural Product Communications</i> , 2019 , 14, 1934578X1984997	0.9	5
47	Prostate cancer biomarkers detection using nanoparticles based electrochemical biosensors. <i>Biosensors and Bioelectronics</i> , 2019 , 137, 213-221	11.8	53
46	Towards sarcosine determination in urine for prostatic carcinoma detection. <i>Sensors and Actuators B: Chemical</i> , 2019 , 287, 380-389	8.5	14
45	Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients. <i>Prostate</i> , 2019 , 79, 234-242	4.2	10

44	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 225-239	5	14
43	Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. <i>European Journal of Cancer</i> , 2020 , 125, 153-163	7.5	3
42	Analysis of Bone Scans in Various Tumor Entities Using a Deep-Learning-Based Artificial Neural Network Algorithm-Evaluation of Diagnostic Performance. <i>Cancers</i> , 2020 , 12,	6.6	9
41	Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. <i>Cancers</i> , 2020 , 12,	6.6	29
40	Characterization of CD147, CA9, and CD70 as Tumor-Specific Markers on Extracellular Vesicles in Clear Cell Renal Cell Carcinoma. <i>Diagnostics</i> , 2020 , 10,	3.8	4
39	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020 , 66, 842-851	5.5	12
38	Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020 , 80, 559-569	4.2	9
37	ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. <i>Translational Andrology and Urology</i> , 2021 , 10, 3986-3999	2.3	1
36	Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters. <i>Frontiers in Oncology</i> , 2021 , 11, 626104	5.3	2
35	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021 , 15, 2453-2465	7.9	4
34	Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients. <i>Annals of Translational Medicine</i> , 2021 , 9, 875	3.2	2
33	Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. <i>BMC Cancer</i> , 2021 , 21, 655	4.8	1
32	Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation. <i>Cancers</i> , 2021 , 13,	6.6	1
31	Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 721659	5.3	0
30	Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. <i>Pharmacology & Therapeutics</i> , 2021 , 228, 107932	13.9	7
29	The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 602493	5.7	5
28	Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. <i>PLoS ONE</i> , 2012 , 7, e44917	3.7	27
27	Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients. <i>Oncotarget</i> , 2017 , 8, 54708-54721	3.3	16

26	Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. <i>Oncotarget</i> , 2014 , 5, 7357-67	3.3	17
25	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 40085-40094	3.3	13
24	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020 , 72, 737-745	4.4	4
23	Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. <i>Translational Andrology and Urology</i> , 2013 , 2, 202-211	2.3	67
22	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2016 , 18, 580-5	2.8	29
21	Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 292-7	7.1	
20	Pharmacodynamic Modeling. <i>Cancer Drug Discovery and Development</i> , 2014 , 193-208	0.3	
19	Introduction. <i>Current Clinical Urology</i> , 2014 , 167-176		
18	Phase III Targeted Treatments. <i>Current Clinical Urology</i> , 2014 , 177-186		
17	Evolution of Clinical States and the Castration Resistant Clinical Paradigm. <i>Current Clinical Urology</i> , 2014 , 9-29		
16	Bone Preservation Strategies for Men on Androgen Deprivation Therapy. 2016 , 231-257		
15	Circulating Tumor Cells (CTCs) and Metastatic Prostate Cancer (mPCa). 2017 , 47-59		
14	Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?. <i>European Journal of Hospital Pharmacy</i> , 2021 , 28, 83-87	1.6	0
13	Vicious cycle of TGF- β signaling in tumor progression and metastasis. <i>American Journal of Clinical and Experimental Urology</i> , 2014 , 2, 149-55	1.6	16
12	Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients. <i>Cells</i> , 2021 , 10,	7.9	1
11	Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 858013 ^{5.7}		0
10	Data_Sheet_1.docx. 2021 ,		
9	Table_1.XLSX. 2021 ,		

8 Table_2.docx. **2021**,

7 Table_3.docx. **2021**,

6 Table_4.xlsx. **2021**,

5 Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer. *Prostate*, 4.2

4 New generation biomarkers for the detection of prostate cancer. **2022**, 12, 100250 ○

3 Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?. **2022**, 23, 1344-1345 ○

2 Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. **2022**, 23, 1398-1408 ○

1 Left testicular and pulmonary metastases of mucinous adenocarcinoma of the prostate after robot-assisted radical prostatectomy. ○